We have previously shown an increase on the ovulation rate of pacu, Piaractus mesopotamicus, using hypophysation with prostaglandin F2α (PGF2α) (HPG protocol) rather than hypophysation (H); only, however, a persistent lack of ovulation in some females could not be further explained by PGF2α and steroid plasma levels at time of ovulation. Considering this, here we compared the meiotic process and steroids and PGF2α levels during spawning induction using both protocols. To that, H and HPG were treated with conventional hypophysation (0.6 mg/kg priming and 5.4 mg/kg resolving dose), and the latter received synthetic PGF2α (2 mL/fish) at resolving dose. A negative control (saline solution), a SPG group (receiving only PGF2α) and a PPG group (receiving priming and PGF2α) were included. An initial PGF2α peak between one to four hours post‐resolving dose (1‐4 hr) occurred in groups receiving PGF2α (HPG, SPG and PPG). Only H and HPG showed a 17α‐20β‐dihydroxy‐4‐pregnen‐3‐one (DHP) peak 4 hr, concomitant with meiosis resumption, and a final PGF2α peak 12 hours. The HPG protocol resulted in higher PGF2α plasma levels for longer periods (1‐4 and 12 hr) than H (single peak 12 hr), occasioning in the former higher and concomitant levels of both PGF2α and DHP at 4 h. Considering that DHP is known to induce expression of prostaglandin receptors in fish, the concomitant plasma peaks of DHP and PGF2α may also explain the ovulation rate gain previously published, using HPG protocol, which can be further improved adjusting the priming dose and defining the exact interval of PGF2α ovulatory action in this species.
We evaluated the annual process of oocyte and ovarian development of the planktivorous Amazonian catfish, the mapará (Hypophthalmus marginatus), aiming to support captive reproduction for domestication. A total of 149 females were captured from the Tocantins River at the Tucuruí Dam (3°49'55"S, 49°39'9"W) in 13 sampling events. For each individual, we evaluated ovary histology and plasma steroid concentrations. Two annual reproductive cycles, with similar characteristics, including a long period of rest, a short vitellogenic stage and a well‐defined spawning season from November to March, were described. A 17β‐estradiol (E2) rise and a 17α,20β‐dihydroxy‐4‐pregnen‐3‐one (DHP) peak were associated with vitellogenesis and spawning season, respectively, in the first cycle but not in the second reproductive cycle. In conclusion, the studied species presents a reproductive cycle similar to that of other migratory total spawners; however, unusually for this group of fish, there were three (but not two) batches of vitellogenic oocytes in “in maturation” and “mature” stage ovaries, pointing to the possibility of more than one spawn during the spawning season.
The aim of this study was to remove the adhesiveness of Pseudoplatystoma fasciatum eggs using solutions of urea for 10, 30, 60 or 90 min (treatments T0 to T3) or in urea for 10 min and washed in tannin (T4). In the control group, eggs were kept in water. After two experiments, we observed that eggs of control group presented the best embryo viability rates, even maintaining egg adhesiveness, being better than the other treatments. The T4 had the worst embryo viability rates. We observed that embryos of the T4 treatment presented reduced growth and formed a separate group when analyzing morphological parameters (egg diameter, total egg area, embryo area and yolk sac area) by multivariate analysis. Concluding, the control group, free of chemicals, provided the best results and is considered the best alternative for the immediate conservation and aquaculture production of P. fasciatum.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.